H.C. Wainwright reiterates Celcuity stock rating on pricing update

Investing.com reports that H.C. Wainwright has reaffirmed its Buy rating and $155 price target for Celcuity Inc (NASDAQ:CELC) following the company's strong second-quarter performance. Despite the stock surging 78% over the past year to $92, InvestingPro data indicates the shares are currently overvalued relative to its Fair Value estimate.

Analysts maintain a Strong Buy consensus with target prices ranging from $140 to $178. Celcuity disclosed a wholesale acquisition cost of $10,000 per vial and $30,000 per cycle, with management expecting a gross-to-net ratio of approximately 80%. The National Comprehensive Cancer Network has named the REVTORPYK regimens as preferred Category 1 options for wild-type patients in second-line settings.

Celcuity has secured coverage across more than 90% of medical-benefit lives ahead of approval and plans to launch its breast cancer drug REVTORPYK via an expanded access program, with commercial shipments expected to begin in late third-quarter 2026.